PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Award to NorDiag ASA for Outstanding Product Line - The 2008 Frost & Sullivan European IVD Market Product Line Strategy Award is conferred on NorDiag ASA in recognition of its extensive range of molecular diagnostics products
Frost & Sullivan Award to NorDiag ASA for Outstanding Product Line

 

NewswireToday - /newswire/ - London, United Kingdom, 2008/10/21 - The 2008 Frost & Sullivan European IVD Market Product Line Strategy Award is conferred on NorDiag ASA in recognition of its extensive range of molecular diagnostics products.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Automated sample preparation for infectious diseases and cancer diagnostics; early diagnosis of colorectal cancer through Genefec III and testing difficult samples for Methicillin resistant S.aureus (MRSA), tuberculosis, sexually transmitted infections (STI) and respiratory pathogens are the core technologies that underpin the company's outstanding product line.

“NorDiag has an impressive product and development portfolio of molecular technology solutions for infectious diseases and cancer diagnostics,” notes Frost & Sullivan Research Analyst Gayathry Ramachandran. “It offers a wide range of instrumentation to perform sample preparation solutions with a focus on difficult samples such as faeces, sputum and urine as well as molecular tests contributing to the early diagnosis of colorectal cancer.”

The company has been highly successful in developing unique sample preparation methods for infectious disease detection. The patented BUGS'n BEADS™ technology filters the sample keeping the nucleic acid intact and free of any amplification inhibitors. This technology can be used for a variety of purposes including the purification of nucleic acids from difficult samples such as sputum, urine and faeces.

“The automated sample preparation technique for cancers such as lung and colorectal cancer, infectious diseases such as tuberculosis, MRSA and STI as well as nucleic acid isolation have demonstrably reduced lab costs, and have multiple applications in a single instrument,” remarks Ramachandran. “In the STI infectious disease detection market, NorDiag has customised automated sample preparation systems and set up for Becton Dickinson's ProbeTec and Roche's Taqman 48 analyzers. With an approximately 15 per cent market share in Scandinavia, NorDiag is a strong competitor in the market for STI sample preparations.”

The company has recently completed the development of a process for automated human DNA isolation from faeces for the testing of colorectal cancer as well as other diseases. NorDiag plans to launch its next generation test (Genefec III) contributing to early diagnostics of colorectal cancer by 2009. The test will be in an automated format and will be positioned as a parallel to Faecal Occult Blood Testing (FOBT). Clinical testing will be completed later this year.

“NorDiag is in collaboration with EXACT Sciences to design an automated nucleic acid sample preparation system from stool samples for the early diagnosis of colorectal cancer,” adds Ramachandran. “This will support the development of low cost, robust molecular technology for the early detection of colorectal cancer.”

The company has successfully placed high/medium throughput systems in hospitals and larger laboratories. NorDiag has four sample preparation instrument platforms with dedicated reagents that effectively meet customer needs of sample throughput, sample volume and sample type. NorDiag will launch a unique and affordable desk top instrument (“Arrow”) in December this year with dedicated reagents, and scalable sample volumes.

“We are honored to receive the Frost & Sullivan 2008 European IVD Market Product Line Strategy Award. NorDiag is committed to providing clinical laboratories with novel, accurate and useful diagnostic tools. We believe that this will give us even more ammunition in reaching our goal of being a leading company in selected niches within molecular diagnostics for human diseases,” says NorDiag CEO Mårten Wigstøl. “The recognition from a well reputed company such as Frost and Sullivan will contribute to building strong credibility among clinical diagnostics laboratories globally”.

The Frost & Sullivan Award for Product Line Strategy is presented this year to a company that has demonstrated the most insight into customer needs and product demands. The recipient company should have optimized its product line by leveraging products with the various price, performance, and feature points required by the market.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

About NorDiag ASA
NorDiag (nordiag.com) is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo – Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD.

Contact:
Mårten Wigstøl
NorDiag ASA
E: morten.wigstol[.]nordiag.com.
DDI: +47 2202 6561.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Award to NorDiag ASA for Outstanding Product Line

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Catherine Brassell 
+44 207 915 7867 catherine.brassell[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)